Cotadutide in T2DM with Dapagliflozin and Metformin

Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing MEDI0382 Arm with Placebo Arm (2 arms). Primary endpoints: Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours and Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs. Started May 2018; status: completed.